The global eczema therapeutics market is characterized by the presence of several players offering a varied range of treatment drugs and therapies including corticosteroids, calcineurin inhibitors, PDE-4 inhibitors, biologics, and antihistamines. These therapies are used for the treatment of eczema conditions such as atopic dermatitis and contact dermatitis. Eczema is a chronic, inflammatory skin disease that mainly affects children but can persist into adulthood. The global rise in eczema incidences due to changing lifestyles, environmental factors, and genetic predispositions is the major driver of market growth.
The Global Eczema Therapeutics Market Demand is estimated to be valued at US$ 21,973.78 Bn in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the eczema therapeutics are Nedmag Industries Mining & Manufacturing B.V., Nabaltec AG., Huber Engineering Materials, Kyowa Chemical Industry Co. Ltd., Konoshima Chemicals Co. Ltd., Tateho Chemical Industries Co., Ltd., Baymag Inc., Sakai Chemical Industries Co. Ltd., Lehmann & Voss & CO. KG., Martin Marietta Materials Inc., Xinyang Mineral Group, Premier Periclase Ltd., Israel Chemicals Ltd., and Premier Magnesia LLC.
Key opportunities in the market include the strong pipeline of novel biologics and new treatment alternatives beyond corticosteroids with better safety and efficacy profiles. The introduction of newer systemic and biologic therapies provide long-term control of moderate-to-severe eczema symptoms.
Globally, the eczema therapeutics market is anticipated to witness high growth in Asia Pacific and Latin America due to rising awareness, expanding healthcare infrastructure and gradual adoption of advanced treatment options in these regions. Manufacturers are also focusing on emerging markets through collaborations.
Market drivers and restrain:
The key driver for eczema therapeutics market is the rising global incidence of eczema primarily due to environmental changes, genetic predisposition and westernized lifestyle changes. According to statistics, over 20% of the global population suffers from eczema with higher prevalence in developed nations. This increasing patient pool drives the demand for effective therapeutic drugs. On the other hand, side effects associated with long term use of corticosteroids as well as high treatment costs of newer biologics are the major restraints for market growth.
Market key restrain:
Development of novel treatment drugs requires huge capital funding and time for clinical development and approvals. This poses a challenge for pharma companies and delays market entry of new drugs thereby impacting overall market growth. Stringent regulatory environment across regions also affects timely introduction of new therapies.
Segment Analysis
The eczema therapeutics market is segmented on the basis of drug class, route of administration, distribution channels and end-uses. Among drug class, emollients & moisturizers segment dominates the eczema therapeutics market as they are first-line treatment and help provide relief from itching and dry skin. Emollients & moisturizers help maintain skin hydration and reduce inflammation.
Regional Analysis
The North American region dominates the global eczema therapeutics market and is expected to continue its dominance during the forecast period. Factors such as increasing healthcare expenditure, rising awareness about the disease, presence of leading pharmaceutical brands and new product launches drive the market in this region. Asia Pacific is expected to be the fastest growing region due to rising population, increase in healthcare spending, growing middle class population and rapid development of healthcare infrastructure.
Get more insights on this topic: Eczema Therapeutics Market
